Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4337762 | 1.00 | S1PR4 (0.42) | S1PR4S1PR1S1PR3S1PR5PPARG | |
| SCHEMBL4343633 | 0.85 | S1PR1 (0.48) | S1PR4S1PR1S1PR3S1PR5PPARG | |
| SCHEMBL4343640 | 0.85 | S1PR1 (0.48) | S1PR4S1PR1S1PR3S1PR5PPARG | |
| SCHEMBL687545 | 0.82 | PPARA (0.48) | S1PR4S1PR1S1PR3S1PR5PPARG | |
| SCHEMBL687546 | 0.82 | PPARA (0.48) | S1PR4S1PR1S1PR3S1PR5PPARG | |
| SCHEMBL3512814 | 0.78 | S1PR1 (0.50) | S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL3508946 | 0.78 | S1PR1 (0.50) | S1PR4S1PR1S1PR3S1PR5 | |
| Hydrochloric Acid SCHEMBL4330918 | 0.77 | S1PR1 (0.49) | S1PR4S1PR1S1PR3S1PR5 | |
| Hydrochloric Acid SCHEMBL4330925 | 0.77 | S1PR1 (0.49) | S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL688475 | 0.76 | PPARG (0.47) | S1PR4S1PR1S1PR3S1PR5PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612238-B2 | Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases | NOVARTIS AG (CH) | 2009-11-03 | — | — | US | disclosed |
| US-20060166940-A1 | Amino-propanol derivatives | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | disclosed |
| EP-1539674-A1 | AMINO-PROPANOL DERIVATIVES | Novartis AG (CH) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024673-A1 | AMINO-PROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166940-A1 | Amino-propanol derivatives | ADRB1, ADRB3, ADRA1D | S1PR4 2376/4885S1PR1 1907/4885S1PR3 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.